Bristol-Myers Squibb Company (BMY) Announces New Clinical Trial for Breast Cancer Drug Iza-bren

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater Associates holds over $142 million worth of shares of BMY, which represents 0.66% of its portfolio.

On June 25, 2025, Bristol-Myers Squibb Company (NYSE:BMY) announced a new update regarding its plans for breast cancer treatments. Under this new development, the company announced a new clinical trial for its experimental breast cancer drug, Iza-bren. The drug, which is considered an alternative to physician-selected chemotherapy options, targets patients with advanced breast cancer who are not suited for standard immunotherapies. The clinical trial for the drug is set to begin on July 15, 2025.

With this development, the company highlights its ongoing commitment to bringing innovation in cancer treatments. Given the competitiveness of the oncology market and Bristol-Myers Squibb Company’s (NYSE:BMY) ongoing progress in the field of breast cancer therapies, investors should expect a positive impact on the company’s long-term growth potential.

Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical company, is focused on oncology, cardiovascular, and immunology treatments. It is among the list of cheap stocks to buy.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Fertilizer Stocks to Buy According to Hedge Funds and Growth Stock Portfolio: 12 Companies with At Least 30% Annual Growth Rates.

Disclosure: None.